Showing results for 
Search instead for 
Did you mean: 

A novel therapeutic target for advanced prostate cancer

Community Manager
Community Manager
0 0 463

A novel potential therapeutic target for advanced prostate cancer.

A recent study by Paschalis et al from the Institute of Cancer Research at the Royal Marsden Hospital London examined the sampled tissue of 74 participants in an effort to search for a new potential therapeutic target site for metastatic castrate resistant prostate cancer.

Translational medicine (TM) is defined as "an interdisciplinary branch of the biomedical field supported by three main pillars: bench side (in the lab), bedside, and community"1. The ultimate aim of TM is to synthesize expertise, resources, disciplines and techniques within these pillars to promote developments in prevention, diagnosis, and therapies. It’s a highly interdisciplinary field, the primary focus of which is to combine assets of various natures within the individual pillars in order to make an impact on the global healthcare system.

Prostate cancer may metastasise (spread) locally in the area surrounding the prostate into neighbouring structures like the bladder or ureters or surrounding lymph nodes (glands) in the pelvis. There may also be distant spread to bones such as the spine, as well as organs including the lungs and liver. Rare sites of metastases may include the brain and adrenal glands. We know that prostate cancer growth and spread is dependant to a great extent on the availability and effects of androgens (testosterone). Therefore, the major objective of treatment for this stage of disease is to suppress the testosterone levels in the body, otherwise known as castration. This can be medical or surgical. Surgical castration involves removal of the testicles (bilateral orchidectomy) which is a more permanent treatment option but obviates the need for ongoing medication or injections. Medical castration or androgen deprivation therapy (because the treatment is depriving the prostate of testosterone), is most commonly used in Australia. Tablets may include bicalutamide or flutamide. Monthly or three-monthly injections using degarelix, leuprolide, goserelin, buserelin may be prescribed. In certain instances, an intravenous chemotherapy drug like docetaxel may be added. Abiraterone and enzalutamide are standards of care, improving both progression-free and overall survival.

Over the course of time the prostate cancer itself develops evolutionary mechanisms to insulate itself from the effects of these medications and hence castrate resistance develops. There are a multiplicity of mechanisms that it employs to create this resistance but they involve adaptations in the androgen receptors in the various tissues of the human body at a molecular level, which render conventional medications unable to target these sites. This is known as persistent androgen receptor signalling. When castrate resistance occurs, there are limited therapeutic options available to manage this stage of disease.

In this study, the investigators explored the concept of endocrine resistance (EnR, a term used interchangeably with castrate resistance). EnR can be mediated by androgen receptor (AR) splice variants, with AR splice variant 7 (AR-V7) arguably the most clinically significant variant. They identified proteins that are central to generating AR-V7 and studied splicing regulatory mechanisms in prostate cancer models. Researchers identified JMJD6 as a key regulator of AR-V7, as evidenced by its upregulation with in vitro (in the lab) endocrine resistance. JMJD6 protein levels increased with castration resistance and were associated with higher AR-V7 levels and shorter survival. Inhibition of JMJD6 reduced prostate cancer cell growth. It is suggested that JMJD6 activity is key to the generation of AR-V7, with the catalytic machinery residing within a druggable pocket (defined as “sites that harbors physiochemical and geometric properties consistent with binding orally bioavailable small molecules”). This relationship between JMJD6 and AR-V7 suggests that JMJD6 may be a potential therapeutic target for metastatic castrate resistant prostate cancer in the future2.


  1. Cohrs RJ, Martin T, Ghahramani P et al. Translational medicine definition by the European Society for translational medicine. New Horizons in Translational Medicine 2014: 2 (3): 86–88.
  2. Paschalis A, Welti J, Neeb AJ. JMJD6 is a druggable oxygenase that regulates AR-V7 expression in prostate cancer. Cancer Res 2021: 81 (4): 1087-1100.











About the Author

Kalli Spencer

MBBCh, FC Urol (SA), MMed (Urol), Dip.Couns (AIPC)

Kalli is an internationally renowned Urological Surgeon, specialising in oncology and robotic surgery. He trained and worked in South Africa, before relocating to Australia where he has worked at Macquarie University Hospital and Westmead Hospital. His passion for what he does extends beyond the operating room, through public health advocacy, education and community awareness of men’s health, cancer and sexuality.

Kalli has been involved with the Prostate Cancer Foundation of Australia for many years, advocating for improved cancer care and facilitating community prostate cancer support groups.

House Rules

To help keep this community a welcoming, supportive and caring place we have put together a small list of dos and don'ts for you to think about when posting on our forum, research blog or video gallery. For further information please see our  terms and conditions.

Adhere to PCFA’s five core values of Integrity, Optimism, Compassion, Respect and Commitment.

Our online forum is for you to share experiences with others and does not contain specific medical, counselling or legal advice.  If you require professional advice specific to your individual circumstances we encourage you to see a medical professional, legal professional or counsellor.

No commercial or promotional activity. While members may share information about resources they have found helpful, the PCFA Online Community forum should not be used for the promotion of goods and services. This includes commercial entities passing themselves off as individuals and people who frequently post links to external health professionals or other services.

Be kind to each other - many people using the community are going through a difficult time. A few kind words can go a long way. Please welcome new posters – it can be very nerve-wracking to post on the forum for the first time.

If you or someone you know is suffering from mental health issues, such as depression or anxiety, we encourage you to seek assistance and contact Beyond Blue Tel:1300 224 636 or Lifeline Tel:13 11 14

Speak your mind freely, but please be sensitive to the feelings and experiences of others - you might not always agree, but you can agree to disagree in a peaceful manner.

Don't use offensive language -if a user is found to be using offensive language during their conversations the moderators reserve the right to edit the thread, without warning.

Don't use all capital letters in your posts - it's considered ‘shouting' online and it makes posts difficult to read.

Give each other the benefit of the doubt - please remember that it is all too easy for the tone and meaning of posts to be misinterpreted. Think carefully before replying to a discussion. it It is important to remember that things written rather than said can feel much stronger, so please bear this in mind when reading other people's messages.

Please respect the moderators - their job is to keep the forum safe and constructive so that everybody gets to have his or her fair say.

Stay on topic - try to focus on the original topic. In particular, don't change subject in the middle of an existing thread - just start a new thread.

Read what's already on the forum before posting - you may be repeating what others have already said or asked.

We want PCFA's Online Community to be a secure and helpful environment for all of the community. So please remember that by using PCFA's Online Community you are agreeing to follow our terms and conditions.